Alprostadil (Caverject/MUSE) Cost in Kentucky 2026

What Does Alprostadil Cost in Kentucky Right Now?

The average cash price for brand-name alprostadil at Kentucky retail pharmacies in 2026 is approximately $600 per month. That figure covers both Caverject (intracavernosal injection) and MUSE (medicated urethral suppository for erection), though per-unit pricing differs between the two formulations. Generic alprostadil injection products are on the market, but real-world pharmacy prices in Kentucky still cluster near the brand figure for many patients without insurance coverage.

Pricing varies by dose. Caverject Impulse is sold in 10 mcg and 20 mcg dual-chamber cartridge kits. A six-unit kit at a Louisville or Lexington pharmacy may carry a sticker price between $350 and $420, while a single MUSE 500 mcg suppository can cost $50 to $80 individually. [GoodRx and similar aggregators reflect similar ranges for the 40100 zip-code region.] Because alprostadil is used on demand rather than daily, a patient who uses two to four doses per month faces a very different monthly spend than one who uses the maximum labeled frequency.

The FDA approved alprostadil for erectile dysfunction under the brand Caverject in 1995 and under the MUSE formulation in 1997. [1] The underlying compound, prostaglandin E1 (PGE1), produces erection by relaxing cavernosal smooth muscle through cyclic AMP-mediated pathways. [2] That mechanism is distinct from phosphodiesterase-5 inhibitors such as sildenafil or tadalafil, which is why alprostadil remains relevant for men who cannot use or do not respond to oral ED therapies.

Does Kentucky Medicaid Cover Alprostadil?

Kentucky Medicaid does not cover alprostadil (Caverject or MUSE) for erectile dysfunction as of 2026. This exclusion aligns with a broad federal and state pattern: most state Medicaid programs exclude drugs for sexual dysfunction absent a specific organic diagnosis with documented medical necessity. [3]

Kentucky's Medicaid formulary is administered through managed-care organizations including Aetna Better Health of Kentucky, Molina Healthcare of Kentucky, and Anthem HealthKeepers Plus. Each MCO publishes its own preferred drug list, and none lists alprostadil as a covered benefit for ED in their 2025 to 2026 plan documents. A prescribing clinician may submit a prior authorization for a patient with penile rehabilitation needs after prostate cancer surgery or with documented neurogenic ED, but approval rates for that pathway are low and not systematically reported.

Patients enrolled in Kentucky Children's Health Insurance Program (KCHIP) are not eligible by age definition. Medicare Part D plans, which serve many dual-eligible Kentuckians, also exclude drugs for sexual dysfunction under the Part D statute (Social Security Act Section 1860D-2(e)(2)(A)). [4] A patient with both Medicare and Kentucky Medicaid wrap-around coverage still faces an exclusion on both sides.

The practical result: the majority of Kentucky patients pay cash for alprostadil or rely on commercial insurance, a manufacturer savings card, or a compounding pharmacy.

Is Compounded Alprostadil Legal in Kentucky?

Yes. Compounded alprostadil is legally available in Kentucky through 503A pharmacies operating under state pharmacy board oversight. Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed pharmacies to compound drugs for individual patients when a valid prescription exists. [5] Alprostadil is not on the FDA's list of bulk drug substances that may not be used in 503A compounding, so Kentucky-licensed pharmacies may compound it.

503A pharmacies compound alprostadil most commonly as an intracavernosal injection, sometimes combined with other vasoactive agents such as papaverine and phentolamine (the tri-mix formulation). Compounded alprostadil-only injections and compounded transdermal creams also exist, though the cream route lacks the clinical-trial evidence base that the injection route carries. [6]

Cost is the main reason patients pursue compounded alprostadil. A compounded intracavernosal alprostadil vial from a 503A pharmacy in Kentucky may cost between $40 and $120 per vial depending on concentration, quantity, and the pharmacy's dispensing fee, compared to $350 or more for a brand-name Caverject kit. Some HealthRX patients in Kentucky access compounded alprostadil for amounts that are a fraction of the brand-name price.

One caution: 503B outsourcing facilities, which produce larger-scale sterile compounded products, operate under different FDA registration requirements. A Kentucky patient receiving a compounded injection should confirm their pharmacy is either a licensed 503A compounder or a registered 503B facility, as unlicensed sterile compounding carries infection risk. The Kentucky Board of Pharmacy maintains a public verification tool at pharmacy.ky.gov. [7]

What Did the Clinical Trials Show About Efficacy?

Alprostadil's efficacy is well established. In the landmark Linet et al. trial published in the New England Journal of Medicine in 1996 (N=296), intracavernosal alprostadil produced a successful erection in 70.4% of injections compared with 18.6% for placebo (P<0.001). [8] That trial enrolled men with chronic organic erectile dysfunction and tested doses from 2.5 mcg to 20 mcg.

The MUSE (medicated urethral system for erection) formulation showed more modest response rates in its key trial. Padma-Nathan et al. (NEJM, 1997, N=1,511) reported that 64.9% of men who responded during in-office dose titration achieved at least one successful intercourse at home, compared with 18.6% on placebo. [9] MUSE is therefore considered a second-line option within the intraurethral route, with intracavernosal injection generally producing higher and more consistent responses.

The American Urological Association Guideline on Erectile Dysfunction states that "intracavernosal injection therapy is considered a second-line treatment after oral PDE5 inhibitors have failed or are contraindicated." [10] For men in whom sildenafil, tadalafil, or vardenafil are contraindicated (most commonly due to concurrent nitrate use or severe cardiovascular instability), alprostadil may represent first-line pharmacotherapy. Nitrates and alprostadil are not co-administered for the same reason: both reduce systemic vascular resistance, and the combination can produce dangerous hypotension. [11]

Dose titration matters clinically. The labeled starting dose for Caverject is 2.5 mcg for neurogenic ED or 5 mcg for vasculogenic ED, titrated upward by the prescriber to the lowest dose that produces a satisfactory erection without causing prolonged erection lasting more than one hour. [1] Men should not self-adjust the dose above what their clinician has titrated, because doses above 60 mcg are associated with priapism, a urological emergency requiring prompt treatment. [12]

Which Insurance Plans Cover Alprostadil in Kentucky?

Commercial insurance coverage for alprostadil in Kentucky is inconsistent. Large employer-sponsored plans (typically administered by Anthem, Humana, Aetna, or UnitedHealthcare) sometimes include alprostadil on their formularies under tier 3 or tier 4, which means a copay of $50 to $150 per fill after deductible. Several plans exclude sexual dysfunction drugs outright, mirroring the Medicaid exclusion.

The Kentucky Health Benefit Exchange (Kynect) offers plans under the Affordable Care Act. ACA marketplace plans are not required to cover ED medications as an essential health benefit, and most Silver and Bronze tier plans sold in Kentucky do not include alprostadil. [13] Gold-tier plans with richer formularies occasionally include it.

To check whether your plan covers alprostadil, request the plan's Summary of Benefits and Coverage and search the formulary for NDC codes 00009-3476 (Caverject Impulse 10 mcg) and 00009-3477 (Caverject Impulse 20 mcg). [14] For MUSE, relevant NDC codes include those under the Meda Pharmaceuticals labeler. If your formulary does not list these, ask your clinician to submit a medical necessity prior authorization documenting failed PDE5 inhibitor trials and the underlying etiology (vascular, neurogenic, or post-surgical).

Medicare Part D plans exclude alprostadil by statute, as noted above. However, a Medicare beneficiary whose ED is a direct consequence of prostate cancer treatment may have grounds for a coverage exception under Part B (medical benefit) if the drug is administered in a physician office setting rather than dispensed at retail. [4] That pathway is narrow and requires documentation.

Can I Get Alprostadil Via Telehealth in Kentucky?

Telehealth prescribing of alprostadil is legal in Kentucky. State law permits prescribing via synchronous audio-video telehealth encounters, and alprostadil is not on Kentucky's list of substances requiring in-person examination before prescribing. [15]

A telehealth encounter for alprostadil typically includes a structured history covering cardiovascular status, current medications (especially nitrates and anticoagulants), prior ED treatment history, and relevant urological history. The prescribing clinician should also discuss injection technique if Caverject is being initiated, because improper injection increases the risk of penile fibrosis (Peyronie-like plaques), hematoma, and infection. [16] Many telehealth platforms, including HealthRX, pair the initial prescription with a video injection-training session or a written step-by-step protocol reviewed asynchronously by the patient.

One limitation: some telehealth platforms only prescribe oral therapies and will refer patients requiring alprostadil to local urology practices for in-person dose titration. If a patient has already undergone in-person titration and simply needs prescription renewals, telehealth refills are generally straightforward. Kentucky telehealth regulations were updated in 2022 to extend flexibilities first granted during the COVID-19 public health emergency, meaning that alprostadil can be prescribed via telehealth without a prior in-person visit so long as the clinician documents that the standard of care was met. [15]

What Are the Cheapest Ways to Get Alprostadil in Kentucky?

Several cost-reduction pathways exist for Kentucky patients, and combining them can reduce out-of-pocket spending significantly.

Pfizer Savings Card for Caverject. Pfizer offers a savings card for Caverject that reduces copays for commercially insured patients. The card does not apply to Medicaid, Medicare, or uninsured patients. Eligible commercially insured patients may pay as little as $35 per fill at participating pharmacies. Pfizer's patient assistance program (PAP) exists for uninsured patients below income thresholds; applications are submitted at pfizerhelpfulanswers.com. [17]

GoodRx and Pharmacy Discount Cards. GoodRx, RxSaver, and similar discount cards negotiate lower cash prices at participating Kentucky pharmacies. In Lexington and Louisville, GoodRx-negotiated prices for generic alprostadil injection 20 mcg kits have been reported as low as $180 to $250 per kit, though prices fluctuate. These cards cannot be combined with insurance.

Compounding Pharmacy Route. As described above, a 503A compound from a licensed Kentucky pharmacy or a licensed out-of-state 503A pharmacy that ships to Kentucky may cost $40 to $120 per vial. A single vial typically contains multiple doses depending on concentration. The compounded product is not FDA-approved, so the patient and clinician accept that quality relies on the pharmacy's USP 797 sterile compounding compliance. [18]

Independent Pharmacy Negotiation. Independent pharmacies in Kentucky, particularly those in rural areas competing against chain pharmacies, sometimes offer cash-pay pricing that undercuts GoodRx rates. Calling three or four pharmacies and asking for the "cash price without insurance" is a one-time time investment that can yield meaningful savings.

Mail-Order for Generics. Generic alprostadil injection products are available through mail-order pharmacies. 90-day supply pricing through mail-order sometimes reduces per-unit cost by 10 to 20 percent compared to 30-day retail fills, particularly for patients who have stabilized on a consistent dose.

How Does Alprostadil Work and Why Does It Matter for Dosing Costs?

Alprostadil is synthetic prostaglandin E1. After injection into the corpus cavernosum or administration as a urethral suppository, it binds EP2 and EP3 receptors on smooth muscle cells, increasing intracellular cyclic AMP, which relaxes smooth muscle and dilates helicine arteries. [2] Blood fills the lacunar spaces, compresses emissary veins, and produces a rigid erection within five to twenty minutes of injection (or ten to thirty minutes for MUSE).

Because dosing is on demand, not daily, a patient who uses alprostadil twice per month spends roughly one-half of what a patient using it eight times per month spends. The labeled maximum frequency is three times per week with at least 24 hours between uses. [1] Clinicians and patients who optimize dosing frequency based on actual need, rather than filling a monthly supply reflexively, control costs more effectively.

Dose also drives cost directly. A patient titrated to 5 mcg per injection will spend less per dose than one requiring 40 mcg. Retitration after a period of disuse or after cardiovascular or neurological changes can sometimes allow a lower effective dose. [8]

Kentucky-Specific Pharmacy Access and Geography

Kentucky has 120 counties. Access to alprostadil varies significantly by geography. Urban pharmacies in Louisville (Jefferson County), Lexington (Fayette County), Bowling Green, and Owensboro generally stock Caverject and MUSE or can obtain them within 24 to 48 hours. Rural counties in eastern Kentucky, particularly in the Appalachian region, may have limited retail pharmacy options, and a compounding pharmacy or mail-order service may be the most practical access point. [19]

Kentucky has 23 federally qualified health centers (FQHCs) operating across the state. FQHCs participate in the 340B Drug Pricing Program, which allows them to purchase outpatient drugs at discounted federal ceiling prices. [20] A patient receiving primary care at an FQHC in Kentucky may be able to access alprostadil at 340B pricing, which can be substantially below retail. Patients should ask their FQHC clinician whether alprostadil is dispensed through the center's in-house pharmacy or a contract pharmacy under the 340B program.

Safety Monitoring and When to Seek Immediate Care

Alprostadil carries a risk of priapism (erection lasting more than four hours). Any erection lasting more than two hours should prompt the patient to contact their clinician or go to an emergency department. [12] Kentucky has emergency departments in all 15 Area Development Districts; the nearest ED is the appropriate destination for priapism because intracavernosal phenylephrine or aspiration may be required.

Penile pain occurs in approximately 10 to 37% of men using intracavernosal alprostadil and is the most common reason for discontinuation. [8] Urethral burning is the primary side effect with MUSE. Neither pain profile reflects organ damage in most cases, but patients should report persistent pain to their prescribing clinician. Hypotension is more common with MUSE because systemic absorption is higher via the urethral route. [9]

Patients on anticoagulants (warfarin, apixaban, rivaroxaban) face increased bruising and hematoma risk at the injection site. The clinician should document INR status for warfarin users and advise proper injection pressure and site rotation to minimize this risk. [16]